Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7… Read More